Idiosyncratic Liver Injury due to Rivaroxaban
Rivaroxaban is an oral direct factor Xa inhibitor that has been used for the primary and secondary prophylaxis of thromboembolic disorders. Once daily dosing makes it an attractive alternative when compared to other Novel Oral Anticoagulants (NOACS). Although, major and minor bleeding manifestatio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2017-12-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/11001/30329_F(P)_PF1(AD_GG)_PFA(MJ_GG).pdf |
| _version_ | 1818527506043502592 |
|---|---|
| author | Aneesh Cherakulam Ratheendran Mukund A Prabhu KU Natarajan Saritha Sekhar |
| author_facet | Aneesh Cherakulam Ratheendran Mukund A Prabhu KU Natarajan Saritha Sekhar |
| author_sort | Aneesh Cherakulam Ratheendran |
| collection | DOAJ |
| description | Rivaroxaban is an oral direct factor Xa inhibitor that has been used for the primary and secondary prophylaxis of thromboembolic
disorders. Once daily dosing makes it an attractive alternative when compared to other Novel Oral Anticoagulants (NOACS). Although,
major and minor bleeding manifestations are commonly associated with rivaroxaban, hepatotoxicity has also been mentioned in the
literature as a possible adverse effect. We report a case of drug induced liver injury in a 29-year-old male patient who was started on
rivaroxaban for prophylaxis following an episode of Pulmonary Thromboembolism (PTE). There was a strong temporal relationship
between the onset of symptoms and drug exposure in our case and the association was further validated by standard criteria. Roussel
Uclaf Causality Assessment Method (RUCAM) score of 7 suggests rivaroxaban as the ‘probable’ culprit for drug induced liver injury
in the present case. The temporal association of starting rivaroxaban and onset of symptoms along with elevated liver enzymes and
bilirubin is a strong point in favour of drug induced liver injury due to rivaroxaban. |
| first_indexed | 2024-12-11T06:36:59Z |
| format | Article |
| id | doaj.art-a802bfefd91248658acb63d4d7b0c999 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-11T06:36:59Z |
| publishDate | 2017-12-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-a802bfefd91248658acb63d4d7b0c9992022-12-22T01:17:21ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2017-12-011112OD08OD0910.7860/JCDR/2017/30329.11001Idiosyncratic Liver Injury due to RivaroxabanAneesh Cherakulam Ratheendran0Mukund A Prabhu1KU Natarajan2Saritha Sekhar3Research Fellow, Department of Adult Cardiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.Assistant Professor, Department of Adult Cardiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.Professor, Department of Adult Cardiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.Associate Professor, Department of Adult Cardiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India. Rivaroxaban is an oral direct factor Xa inhibitor that has been used for the primary and secondary prophylaxis of thromboembolic disorders. Once daily dosing makes it an attractive alternative when compared to other Novel Oral Anticoagulants (NOACS). Although, major and minor bleeding manifestations are commonly associated with rivaroxaban, hepatotoxicity has also been mentioned in the literature as a possible adverse effect. We report a case of drug induced liver injury in a 29-year-old male patient who was started on rivaroxaban for prophylaxis following an episode of Pulmonary Thromboembolism (PTE). There was a strong temporal relationship between the onset of symptoms and drug exposure in our case and the association was further validated by standard criteria. Roussel Uclaf Causality Assessment Method (RUCAM) score of 7 suggests rivaroxaban as the ‘probable’ culprit for drug induced liver injury in the present case. The temporal association of starting rivaroxaban and onset of symptoms along with elevated liver enzymes and bilirubin is a strong point in favour of drug induced liver injury due to rivaroxaban.https://jcdr.net/articles/PDF/11001/30329_F(P)_PF1(AD_GG)_PFA(MJ_GG).pdfdrug induced liverfactor xa inhibitornewer oral anticoagulantspulmonary embolism |
| spellingShingle | Aneesh Cherakulam Ratheendran Mukund A Prabhu KU Natarajan Saritha Sekhar Idiosyncratic Liver Injury due to Rivaroxaban Journal of Clinical and Diagnostic Research drug induced liver factor xa inhibitor newer oral anticoagulants pulmonary embolism |
| title | Idiosyncratic Liver Injury due to Rivaroxaban |
| title_full | Idiosyncratic Liver Injury due to Rivaroxaban |
| title_fullStr | Idiosyncratic Liver Injury due to Rivaroxaban |
| title_full_unstemmed | Idiosyncratic Liver Injury due to Rivaroxaban |
| title_short | Idiosyncratic Liver Injury due to Rivaroxaban |
| title_sort | idiosyncratic liver injury due to rivaroxaban |
| topic | drug induced liver factor xa inhibitor newer oral anticoagulants pulmonary embolism |
| url | https://jcdr.net/articles/PDF/11001/30329_F(P)_PF1(AD_GG)_PFA(MJ_GG).pdf |
| work_keys_str_mv | AT aneeshcherakulamratheendran idiosyncraticliverinjuryduetorivaroxaban AT mukundaprabhu idiosyncraticliverinjuryduetorivaroxaban AT kunatarajan idiosyncraticliverinjuryduetorivaroxaban AT sarithasekhar idiosyncraticliverinjuryduetorivaroxaban |